Platform for breakthrough mental health research and treatment
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Osmind is a San Francisco-based public benefit corporation building a psychiatry-specific technology, services, and real-world-evidence platform for interventional mental health care, with products spanning EHR, billing/RCM, prior authorization, and a clinic network for practices treating conditions such as Spravato, TMS, ketamine, and psychedelic medicine.
Primary product
Interventional psychiatry EHR, billing/RCM, prior authorization, and practice-network platform
Founded
2020
Headquarters
1857 Market Street, San Francisco, CA 94103, United States
Team size
50-60
Work style
Hybrid
Industry
Mental Health Care
Sub-industry
Psychiatry software and interventional psychiatry practice management
0 jobs at Osmind
Check back later for new openings
Offices
Business model
Leadership
Co-founder and CEO
Co-founder and President
Chief Medical Officer
Adrian Vera
Chief Technology Officer
VP of Finance
VP of Operations
VP of Growth
Investors
Mission-driven, evidence-oriented, and highly collaborative. Osmind describes its team as scientists, technologists, psychiatrists, and other mission-driven professionals, and says its Bay Area team works in a hybrid/distributed model with regular office days and occasional all-hands offsites.
Work style
Hybrid
Compensation
Public job postings show competitive tech compensation plus equity, with recent engineering roles advertising roughly $150,150-$200,000 for senior engineers and $200,000-$240,000 for staff engineers, alongside broad benefits.
Benefits
Pricing
Hybrid model: per-clinician SaaS for Osmind One plus custom/performance-based service tiers for Osmind 360 and Care Network, with add-ons for e-prescribing, labs, and payment processing.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$20M-$30M (third-party estimate)
Estimated monthly visits
130.8K
Traffic estimate as of Jun 2026
GlobeNewswire · Jun 2026
A peer-reviewed poster co-authored by Osmind researchers compared outcomes in 8,224 IV ketamine patients and 1,830 intranasal esketamine patients, reporting higher remission and response rates for IV ketamine in routine care.
Business Wire · Apr 2026
Compass Pathways said it is collaborating with Osmind to help independent clinics prepare for potential psychedelic treatment delivery, with Osmind's network described as 1,000+ clinics.
Business Wire · Apr 2026
Osmind announced an exclusive partnership with CareNet GPO to improve purchasing power and operational support for independent psychiatry practices, including negotiated savings, buy-and-bill support, and access to the Psychiatry Collective.
Business Wire · May 2025
Osmind named Adrian Vera as CTO, Kelsey Friedman as VP of Operations, and Sabas Rodriguez as VP of Growth to support product, operations, and go-to-market expansion.
Business Wire · Jan 2025
Osmind announced William Sauvé as Chief Medical Officer, signaling a deepening focus on interventional psychiatric care and network growth.